Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Buying started ...

<< Previous

Bullboard Posts

Next >>

Comment by davgroon Nov 17, 2022 11:40am

160 Views

Post# 35107055

RE:RE:RE:Buying started ...

nobeard wrote:
Would some one be able to shed some light on how Joe bought shares at 0.39 when we haven't been that low?

Hey nobeard, I can see from a previous post of yours that you have the Dumpster on ignore so you won't see his response to your question. So here is my answer:

On November 16th Joseph Stauffer acquired 13,530 shares in the public market at a price of USD $0.362. His was the only trade in ATBPF on the US market on that day (see below).

Close Prices Last 3 Months

Price/volumes not adjusted for restructures